Lexaria Bioscience (LEXX) Equity Average (2012 - 2026)

Lexaria Bioscience has disclosed Equity Average across 15 years of filings, most recently posting $5.6 million for Q1 2026.

• Equity Average for Q1 2026 came in at $5.6 million, down 31.13% year-over-year; the trailing twelve-month figure through Feb 2026 was $5.6 million (down 31.13% YoY), and the FY2025 annual result was $5.3 million, up 2.99% from the prior year.
• Equity Average came in at $5.6 million for Q1 2026 at Lexaria Bioscience, up from $3.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $11.3 million in Q1 2022 to a low of $3.0 million in Q4 2023.
• The 5-year median for Equity Average is $6.0 million (2025), against an average of $6.5 million.
• Across the five-year window, Equity Average sank 59.38% in 2023 and jumped 181.74% in 2024, its largest moves.
• Lexaria Bioscience's Equity Average stood at $6.8 million in 2022, then sank by 55.38% to $3.0 million in 2023, then jumped by 181.74% to $8.5 million in 2024, then tumbled by 55.94% to $3.8 million in 2025, then jumped by 48.09% to $5.6 million in 2026.
• The last three Equity Average figures came in at $5.6 million (Q1 2026), $3.8 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.